This dose escalation strategy helps minimise gastrointestinal side effects whilst allowing the body to adapt to the medication's effects
As shown in Scheme 10
If youre ready to compare GLP-1 telehealth options, our quiz can help Find My GLP-1 References, Methodology, and Update Log How This Guide Was Researched All clinical trial data in this guide comes from one of four source types: Peer-reviewed publications (New England Journal of Medicine, Nature Medicine, JAMA) Official Eli Lilly press releases (via investor.lilly.com and PR Newswire) ClinicalTrials.gov registrations (NCT numbers linked throughout) FDA official communications (warning letters, safety advisories) We do not cite social media posts, unregulated seller claims, anecdotal reports, or promotional materials from non-clinical sources
Nevertheless, these are individual cases, not clinical patterns
That gap between official status and retail-style marketing is exactly the kind of thing patients should pay attention to
Given that fluoropyrimidine-based therapy will remain a major treatment modality for patients with advanced CRC for the foreseeable future, the need for better, more effective chemotherapy combinations in biologically selected populations to overcome drug resistance is an urgent, unmet need for patients with CRC worldwide